Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 49

References for PMC Articles for PubMed (Select 20150394)

1.

Alpha lipoic acid in burning mouth syndrome--a randomized double-blind placebo-controlled trial.

Cavalcanti DR, da Silveira FR.

J Oral Pathol Med. 2009 Mar;38(3):254-61. doi: 10.1111/j.1600-0714.2008.00735.x. Epub 2009 Jan 23.

PMID:
19175713
2.

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.

O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L; FTY720 D2201 Study Group.

Neurology. 2009 Jan 6;72(1):73-9. doi: 10.1212/01.wnl.0000338569.32367.3d.

PMID:
19122034
3.

Alpha-lipoic acid supplementation and diabetes.

Singh U, Jialal I.

Nutr Rev. 2008 Nov;66(11):646-57. doi: 10.1111/j.1753-4887.2008.00118.x. Review. Retraction in: Nutr Rev. 2012 Aug;70(8):482.

4.

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Menge T, Weber MS, Hemmer B, Kieseier BC, von Büdingen HC, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stüve O.

Drugs. 2008;68(17):2445-68. doi: 10.2165/0003495-200868170-00004. Review.

PMID:
19016573
5.

Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study.

López-Jornet P, Camacho-Alonso F, Leon-Espinosa S.

J Oral Rehabil. 2009 Jan;36(1):52-7. doi: 10.1111/j.1365-2842.2008.01914.x. Epub 2008 Oct 18.

PMID:
18976257
6.

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators.

Lancet. 2008 Oct 25;372(9648):1463-72. doi: 10.1016/S0140-6736(08)61619-0. Erratum in: Lancet. 2009 Apr 18;373(9672):1340.

PMID:
18970976
7.

Emerging oral drugs for multiple sclerosis.

Gasperini C, Cefaro LA, Borriello G, Tosto G, Prosperini L, Pozzilli C.

Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77. doi: 10.1517/14728214.13.3.465 . Review.

PMID:
18764723
8.

Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study.

Carbone M, Pentenero M, Carrozzo M, Ippolito A, Gandolfo S.

Eur J Pain. 2009 May;13(5):492-6. doi: 10.1016/j.ejpain.2008.06.004. Epub 2008 Dec 9.

PMID:
18675569
9.

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group.

Lancet. 2008 Jun 21;371(9630):2085-92. doi: 10.1016/S0140-6736(08)60918-6.

PMID:
18572078
10.

Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits IFN gamma synthesis and cellular cytotoxicity in NK cells.

Salinthone S, Schillace RV, Marracci GH, Bourdette DN, Carr DW.

J Neuroimmunol. 2008 Aug 13;199(1-2):46-55. doi: 10.1016/j.jneuroim.2008.05.003. Epub 2008 Jun 17.

11.

Diagnosis and treatment of multiple sclerosis.

Myhr KM.

Acta Neurol Scand Suppl. 2008;188:12-21. doi: 10.1111/j.1600-0404.2008.01026.x. Review.

PMID:
18439216
12.

Effects of alpha-lipoic acid on ischemia-reperfusion-induced renal dysfunction in rats.

Bae EH, Lee KS, Lee J, Ma SK, Kim NH, Choi KC, Frøkiaer J, Nielsen S, Kim SY, Kim SZ, Kim SH, Kim SW.

Am J Physiol Renal Physiol. 2008 Jan;294(1):F272-80. Epub 2007 Nov 21.

13.

Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis.

Hager K, Kenklies M, McAfoose J, Engel J, Münch G.

J Neural Transm Suppl. 2007;(72):189-93.

PMID:
17982894
14.

Effects of alpha-lipoic acid supplementation in peripheral arterial disease: a pilot study.

Vincent HK, Bourguignon CM, Vincent KR, Taylor AG.

J Altern Complement Med. 2007 Jun;13(5):577-84.

PMID:
17604563
15.

Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.

Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, Mercier RC.

Antimicrob Agents Chemother. 2007 Aug;51(8):2741-7. Epub 2007 Jun 4.

16.

A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis.

Magis D, Ambrosini A, Sándor P, Jacquy J, Laloux P, Schoenen J.

Headache. 2007 Jan;47(1):52-7.

PMID:
17355494
17.

Lipoic acid stimulates cAMP production in T lymphocytes and NK cells.

Schillace RV, Pisenti N, Pattamanuch N, Galligan S, Marracci GH, Bourdette DN, Carr DW.

Biochem Biophys Res Commun. 2007 Mar 2;354(1):259-64. Epub 2007 Jan 3.

18.

Glomerular volume and renal histology in obese and non-obese living kidney donors.

Rea DJ, Heimbach JK, Grande JP, Textor SC, Taler SJ, Prieto M, Larson TS, Cosio FG, Stegall MD.

Kidney Int. 2006 Nov;70(9):1636-41. Epub 2006 Sep 6.

PMID:
16955108
19.

Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity.

Schreibelt G, Musters RJ, Reijerkerk A, de Groot LR, van der Pol SM, Hendrikx EM, Döpp ED, Dijkstra CD, Drukarch B, de Vries HE.

J Immunol. 2006 Aug 15;177(4):2630-7.

20.

The molecular machinery for cAMP-dependent immunomodulation in T-cells.

Taskén K, Stokka AJ.

Biochem Soc Trans. 2006 Aug;34(Pt 4):476-9. Review.

PMID:
16856837
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk